Bruce Ruggeri

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

Jin Q. Cheng, Bruce Ruggeri, Willemijn M. Klein et al. · Proceedings of the National Academy of Sciences · 1996 · 793 citations

Medicine, Molecular Biology, Oncology +17

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Michał Marzec, Qian Zhang, Ami Goradia et al. · Proceedings of the National Academy of Sciences · 2008 · 723 citations · Full text

Medicine, Cancer Biology, Oncology +16

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 474 citations

Medicine, Oncology, Pharmacology +11

Amplification and overexpression of theAKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

Bruce Ruggeri, Lingyi Huang, Moira Wood et al. · Molecular Carcinogenesis · 1998 · 316 citations

Medicine, Cancer Biology, Oncology +17

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Roberto Piva, Bruce Ruggeri, Michael Williams et al. · Blood · 2007 · 253 citations · Full text

Medicine, Oncology, Pharmacology +9